PROCEPT BioRobotics (NASDAQ:PRCT) and Arrayit (OTCMKTS:ARYC) Head-To-Head Analysis

Arrayit (OTCMKTS:ARYC) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of current ratings and price targets for Arrayit and PROCEPT BioRobotics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrayit	0	0	0	0	0.00
PROCEPT BioRobotics	2	4	8	0	2.43

PROCEPT BioRobotics has a consensus target price of $41.45, indicating a potential upside of 42.95%. Given PROCEPT BioRobotics’ stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Arrayit.

Valuation & Earnings

This table compares Arrayit and PROCEPT BioRobotics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrayit	N/A	N/A	N/A	N/A	N/A
PROCEPT BioRobotics	$308.05 million	5.36	-$95.57 million	($1.82)	-15.93

Arrayit has higher earnings, but lower revenue than PROCEPT BioRobotics.

Institutional and Insider Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 58.0% of Arrayit shares are owned by insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Arrayit has a beta of -0.22, suggesting that its stock price is 122% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Arrayit and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arrayit	N/A	N/A	N/A
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

Summary

PROCEPT BioRobotics beats Arrayit on 6 of the 10 factors compared between the two stocks.

About Arrayit

Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.